Chinese hotel manager Hong Chun had trouble using chopsticks after a minor stroke and sought treatment at a large Shanghai hospital where doctors injected what they said were donor stem cells into his spinal cord and buttocks, according to his father and cousin.
Leaving hospital the next day, Hong, 27, fell so ill he had to be taken off the train and rushed to another hospital. Doctors were unable to save him and he was declared brain dead before dying a month later.
Desperate for help, patients with incurable diseases are admitting themselves into hospitals in China for “stem cell therapies,” but experts say such treatments are backed by little or no scientific evidence and are at best experimental.
Some of these cases involve large general hospitals where patients pay thousands, even tens of thousands, of US dollars for treatments that are advertised online. Patients have come away with little or no improvement and a number have died, according to patients, doctors and relatives of patients.
Hong paid 30,000 yuan (US$4,696) to the People’s Liberation Army’s (PLA) 455 PLA Hospital in Shanghai for the treatment last year, according to hospital receipts.
His father, Hong Gensho, travelled to Shanghai to seek an explanation. Hospital administrators told him his son didn’t die in their hospital, paid him 80,000 yuan (US$12,523) and told him not to pursue the matter.
“I am miserable, it’s like my son was worth only 80,000 yuan. It’s not about money. Our human rights, our place in this society, are not respected. I am devastated. If he hadn’t sought treatment, he would not have died,” the elder Hong, 61, said.
“I can’t get my son back, but people must know about these stem cell therapies and no one must be deceived,” he added.
Experts have raised the alarm on patients turning up at clinics and hospitals in China, Mexico, India, Turkey, Russia and elsewhere for stem cell therapies that have not undergone clinical trials and which are not recognized as standard treatment.
Patients often pay fees of US$20,000 and more for such therapies after exhausting conventional treatments.
“Stem cell tourism is regarded as ethically problematic because patients receive unproven therapies from untrustworthy sources,” David Resnik at the US National Institute of Environmental Health Sciences and Zubin Master at the University of Alberta in Canada wrote in a paper published in the journal European Molecular Biology Organisation.
Echoing the same concerns, George Daley at the Harvard Stem Cell Institute and Harvard Medical School said he was swamped by enquiries from patients asking about therapies in China and Brazil for diseases from Alzheimer’s to spinal cord injuries.
“What I’m talking about are the less legitimate treatments that have not even undergone clinical trials but are directly marketed therapies ... We really have no idea how to use stem cells for these treatments,” Daley said.
When contacted, a director at the PLA 455 Hospital, who declined to be identified, said: “There are always good and bad outcomes. No therapy can guarantee success to everyone ... Besides, you don’t have a better alternative.”
“As for patients dying, all deaths must be investigated. What caused the death? If our treatment caused the death, the patient [relatives] can seek redress. If it is a death caused by old age and sickness, then there is nothing I can say,” he added.
China’s Ministry of Health did not respond to questions on stem cell therapies being offered in the country.
Suffering from late-stage liver cirrhosis caused by a lifelong hepatitis B virus infection, Fan Hongkun was led to believe her body would spontaneously grow a healthy liver once stem cells were transplanted.
“We saw the therapy advertised online and talked to the doctor over the phone. He said stem cells were like seeds, after being planted on a liver, they grow, divide and spread and finally form a healthy liver,” said Fan’s son, Zhou Junjie.
Fan, 63, was so convinced, she admitted herself into Beijing Military General Hospital, whose Web site still carries information on the stem cell therapies it offers.
“My mother said the PLA does not lie. That’s why she trusted them,” Zhou said.
Doctors there took her off the drug lamivudine for four weeks to “prepare her for the stem cell therapy.” But she fell into a coma before doctors could treat her.
Sold under the brand Epivir by GlaxoSmithKline PLC , lamivudine minimizes liver damage by blocking the hepatitis B virus from replicating. Fan’s family learned later from other doctors that she suffered a sudden surge of the virus after she stopped her medication, which pushed her into a coma and killed her.
According to documents, her family sued the hospital, but the case was dismissed by a Chinese court.
When contacted, a doctor at the hospital, who declined to be identified, said the entire procedure to transplant stem cells into a patient’s liver takes only a day.
“We extract the patient’s bone marrow cells and isolate the stem cells, which are then inserted into the liver,” the doctor said. “We extract bone marrow cells in the morning and in the afternoon we inject them [stem cells] into the liver. Yes, all it takes is a day. Very fast.”
Advertisements for these treatments remain on the hospital’s Web site.
In Ireland, many patients have returned from treatments abroad with no improvement, but they are less willing to talk.
“Virtually none will go on record to state they have been conned. This is mainly because many patients have serious immediate health concerns and they need to focus on that,” said Stephen Sullivan, chief scientific officer of the Irish Stem Cell Foundation.
“Patients are also reluctant to come forward as they are embarrassed at spending lots of money against professional medical advice. Some patients will even claim improvement when there is no measurable improvement,” he added.
Researchers believe regenerative medicine will be a powerful form of therapy in the future. Stem cells are immature, master cells in the body that can grow into any kind of human cell or tissue. Scientists are exploring how to use them to treat a variety of diseases and disorders, including cancer, diabetes and injuries.
However, for now, they stress that only one type of stem cell therapy has been proven to work.
“Only bone marrow transplants for diseases such as leukemia, lymphoma are backed by solid evidence and are well-established clinical procedures. The others are not up to that level,” said David Siu, clinical associate professor at the cardiology division of Hong Kong’s Queen Mary Hospital.
“There is evidence that certain stem cells can grow into new tissue, but do they provide a therapeutic effect? We don’t have the evidence yet. Some are in clinical research,” he said.
For the conditions highlighted in this article — disability from strokes and liver cirrhosis — experts say there are no proven stem cell treatments.
In their paper, Resnik and Master said while most countries had rules governing research on people and medical malpractice, they did not apply directly to stem cell therapy. When doctors encounter strict regimes, they can simply move to other countries with more permissive legal environments.
Experimental stem cell therapies, however, may be legitimately offered to patients, but these must be carried out within the framework of clinical trials that are approved by regulatory boards that ensure ethical standards are met.
“When experimental stem cell therapy is used on patients, it is not performed on an ad-hoc basis, but within the framework of a proper clinical trial prepared beforehand,” Siu said. “It has to follow a rigorous methodology: What are the risks, what can and cannot be done? If the results are negative, what are the rescue and safety measures?”
Sullivan urged patients to be on the lookout for scams. Suspicious signs include being asked for large sums of money up front, being told there are no risks and being offered no post-therapy care.
Patients should be told how they will be treated, what stem cells are used and where they come from. They should not accept any therapy based on hearsay, or without the treatment being validated at least in part by peer review, he said.
Resnik and Master urged stem cell scientists, who have control over stem cell lines, to help stop these scams by not releasing such materials to doctors or clinics if they cannot produce proof of conducting a genuine clinical trial.
“This would ensure that the stem cells and other materials are going to be used in the course of responsible biomedical research, a legally sanctioned clinical trial or in responsible medical innovation,” they said.
Additional reporting by Julie Steenhuysen, Zoey Zhang, Viola Ho and Li Hui
Concerns that the US might abandon Taiwan are often overstated. While US President Donald Trump’s handling of Ukraine raised unease in Taiwan, it is crucial to recognize that Taiwan is not Ukraine. Under Trump, the US views Ukraine largely as a European problem, whereas the Indo-Pacific region remains its primary geopolitical focus. Taipei holds immense strategic value for Washington and is unlikely to be treated as a bargaining chip in US-China relations. Trump’s vision of “making America great again” would be directly undermined by any move to abandon Taiwan. Despite the rhetoric of “America First,” the Trump administration understands the necessity of
US President Donald Trump’s challenge to domestic American economic-political priorities, and abroad to the global balance of power, are not a threat to the security of Taiwan. Trump’s success can go far to contain the real threat — the Chinese Communist Party’s (CCP) surge to hegemony — while offering expanded defensive opportunities for Taiwan. In a stunning affirmation of the CCP policy of “forceful reunification,” an obscene euphemism for the invasion of Taiwan and the destruction of its democracy, on March 13, 2024, the People’s Liberation Army’s (PLA) used Chinese social media platforms to show the first-time linkage of three new
If you had a vision of the future where China did not dominate the global car industry, you can kiss those dreams goodbye. That is because US President Donald Trump’s promised 25 percent tariff on auto imports takes an ax to the only bits of the emerging electric vehicle (EV) supply chain that are not already dominated by Beijing. The biggest losers when the levies take effect this week would be Japan and South Korea. They account for one-third of the cars imported into the US, and as much as two-thirds of those imported from outside North America. (Mexico and Canada, while
I have heard people equate the government’s stance on resisting forced unification with China or the conditional reinstatement of the military court system with the rise of the Nazis before World War II. The comparison is absurd. There is no meaningful parallel between the government and Nazi Germany, nor does such a mindset exist within the general public in Taiwan. It is important to remember that the German public bore some responsibility for the horrors of the Holocaust. Post-World War II Germany’s transitional justice efforts were rooted in a national reckoning and introspection. Many Jews were sent to concentration camps not
RSS